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Abstract A functionally active analogue of neurotensin, neuro-
tensin(8^13), has been observed whilst bound to the agonist-
binding site of the rat neurotensin receptor by nuclear magnetic
resonance (NMR). Through the application of slow magic angle
sample spinning and high-power proton decoupling, sufficient
resolution and sensitivity were obtained in the carbon-13
spectrum to allow an assignment of many of the side chain
resonances arising from uniformly carbon-13/nitrogen-15-
labelled neurotensin(8^13) whilst bound to the neurotensin
receptor. Significant perturbations in carbon-13 chemical shift
were observed upon the binding of the neurotensin(8^13) to the
receptor. Most importantly significant shifts were observed in
both the carboxy terminus and tyrosine side chain of the
neurotensin(8^13), suggesting that these sites are important in
the interaction of the neurotensin with the agonist-binding site
on the neurotensin receptor. Conversely, no perturbations
were observed for the carbon-13 sites within the guanidinium
groups of the arginine side chains, indicating little interaction
with the receptor-binding site, or a shielding of the local
environment by the surrounding nitrogen atoms. These NMR
observations lend further support to previous structure^activity
studies, site-directed mutagenesis and modelling studies of the
agonist-binding site of the neurotensin receptor, from which the
same specific residues for which NMR perturbations were
observed are important for neurotensin receptor activation by
neurotensin. ß 2002 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The neurotensin receptor is a member of the G-protein
coupled receptor (GPCR) family of transmembrane proteins,
and is activated upon binding of the agonist neurotensin, a
basic tridecapeptide, to the extracellular surface of cells. The
neurotensin receptor is found widely in both the central and
peripheral nervous system. In the periphery, the neurotensin
receptor stimulates smooth muscle contraction [1] while in the
central nervous system, the neurotensin receptor mediates a
variety of activities including antinociception, hypothermia
and increased locomotor activity [2^4]. These e¡ects are prob-
ably mediated through the regulation of the mesolimbic and
negrostriatal dopamine pathways [5]. As a result, the pharma-
cological action of neurotensin is similar to that observed for
dopamine, where compounds function as antipsychotics [6^8],
and intervention may provide useful insights into the develop-
ment of treatments for conditions such as schizophrenia [5]
and Parkinson’s disease [5].
To date no direct high-resolution structural information is
available for the neurotensin receptor, possibly due to the
limited success at producing 2D and 3D crystals for di¡rac-
tion studies and also to the unfavourable relaxation rates
associated with the size of membrane systems which hinder
conventional high-resolution solution-state nuclear magnetic
resonance (NMR) studies. Nevertheless, sequence analysis
and modelling studies of the neurotensin receptor have sug-
gested that the receptor adopts a seven transmembrane topol-
ogy typical for the GPCR class of proteins [9]. Chimeric re-
ceptor studies [10] and site-directed mutagenesis analysis [9,11]
have shown the location of the agonist-binding site on the
receptor. These studies suggest that the third extracellular
loop and the sixth transmembrane domain of the receptor
are involved in the binding of the C-terminal domain of neu-
rotensin. Solution-state NMR studies (NOEs and J-couplings)
of the agonist, neurotensin, in the absence of receptor have
revealed that no preferred conformation exists in solution
[12]. Extensions of these studies to neurotensin in the pres-
ence of the membrane mimetic sodium dodecyl-d25 sulphate,
again con¢rm that no preferred conformation was adopted,
although some ordering of charged residues on the surface of
the micelles was observed [13]. In addition, extensive struc-
ture^function studies have been performed [14,15] indicating
that residues 8^13 in the neurotensin are su⁄cient to elicit
binding and activation of the neurotensin receptor.
The current study focusses on the application of NMR
methodology to analyse the conformation and environment
adopted by the neurotensin analogue, neurotensin(8^13),
upon the binding to the detergent-solubilised neurotensin re-
ceptor. Typically, large detergent^receptor complexes produce
poor resolution in the solution-state NMR spectrum due to a
combination of residual anisotropic interactions caused by
slow rotational di¡usion, susceptibility broadening [16] and
residual B0 inhomogeneities. Through the application of
slow magic angle sample spinning (500 Hz) and high-power
proton decoupling (70 kHz), many of these anisotropic inter-
actions were averaged su⁄ciently to allow the acquisition of
high-resolution-like spectra, with su⁄cient intensity to permit
the assignment of many of the side chain resonances for neu-
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rotensin(8^13) whilst bound to the agonist-binding site on the
detergent-solubilised receptor. A detailed analysis of the per-
turbations in chemical shifts upon binding of neurotensin(8^
13) to the receptor has allowed us to identify key sites that are
important for the interaction of neurotensin with the receptor.
Our results are interpreted in the context of current models
proposed on the basis of site-directed mutagenesis and struc-
ture^activity studies.
2. Materials and methods
2.1. Solid phase synthesis of neurotensin(8^13)
Neurotensin(8^13) was synthesised using conventional FMOC solid
phase synthesis at the Oxford Centre for Molecular Sciences. Uni-
formly labelled amino acids (Promochem, UK) were protected and
puri¢ed using standard amino acid protection protocols [17], and the
nature and purity of the compounds was con¢rmed by electrospray
mass spectroscopy and thin layer chromatography. Following solid
phase synthesis, the peptide was puri¢ed by reverse phase high-per-
formance liquid chromatography, eluting at an acetonitrile concentra-
tion of 27% comparable with standard neurotensin(8^13) (Sigma,
UK). Electrospray mass spectroscopy of the ¢nal product gave a
single molecular species with molecular weight of 868 Da, consistent
with the uniform carbon-13 and nitrogen-15 labelling of neuroten-
sin(8^13).
2.2. Expression and puri¢cation of the neurotensin receptor
Detergent-solubilised rat neurotensin receptor was obtained as de-
scribed by Grisshammer [18^20]. For expression Escherichia coli strain
DH5K was grown on double strength TY medium [18^20] containing
ampicillin (100 g/ml) and 0.2% glucose. A NTR fusion protein was
expressed from the pRG/III-hs-MBPP-T43NTR-TrxA-H10 plasmid
obtained from Dr R. Grisshammer [18^20]. This plasmid expresses
a hybrid protein composed of a truncated neurotensin receptor with
a maltose-binding protein, together with it periplasmic targeting se-
quence, attached to the N-terminus and thioredoxin and a deca-his
tag to aid stability and puri¢cation to the C-terminus. The E. coli
DH5K were grown in 400 ml of medium in a 1 l £ask at 37‡C until
OD600 reached 0.7. The cultures were subsequently induced with 0.5
mM isopropyl-L-galactoside. The temperature was then lowered to
20‡C and further incubated for 40 h. The cells were harvested by
centrifugation, £ash frozen in liquid nitrogen and stored at 370‡C.
The puri¢cation of heterologously expressed neurotensin receptor
was performed as previously described by Grisshammer [18^20].
Brie£y, 200 g of cell paste were resuspended in 1.2 l of neurotensin
bu¡er (50 mM Tris, pH 7.4, 0.2 M NaCl, 30% glycerol, 0.5% CHAPS,
0.1% CHS, 0.1% LM) containing pepstatin A, leupeptin A, phenyl-
methylsulfonyl £uoride, lysozyme and DNase. The cells were then
broken using a £ow through sonicator and the lysate clari¢ed by
centrifugation. The supernatant was then loaded onto a Qiagen
NTA nickel a⁄nity column in 1 mM imidazole at a £ow rate of 10
ml min31. The neurotensin receptor was then eluted in neurotensin
bu¡er containing 350 mM imidazole. The eluate was then concen-
trated using an Amicon stirred cell with YM-30 membrane.
The bu¡er was subsequently exchanged to a low-salt bu¡er (50 mM
Tris, pH 7.4, 1 mM EDTA, 20 mM NaCl, 30% glycerol, 0.5%
CHAPS, 0.1% CHS, 0.1% LM) using a 150 ml Sephadex-G25 column.
The active receptor was then puri¢ed using a neurotensin a⁄nity
column [18,19]. The a⁄nity column was equilibrated with low-salt
bu¡er and the fraction containing the neurotensin receptor loaded
at 0.5 ml min31. Following washing with both low-salt bu¡er and
200 mM KCl bu¡er, the active neurotensin receptor was eluted using
a high-salt bu¡er (50 mM Tris, pH 7.4, 1 mM EDTA, 1.0 M NaCl,
30% glycerol, 0.5% CHAPS, 0.1% CHS, 0.1% LM). Prior to NMR
studies the puri¢ed neurotensin receptor was returned to desalting
bu¡er and concentrated using a stirred cell Amicon and Centricon
containing an YM-30 membrane.
Prior to NMR measurements the concentration of protein was de-
termined using an amido black protein assay. The speci¢c activity of
the sample was determined using a tritiated-neurotensin binding assay
[18,20]. Typically the speci¢c activity of the sample prior to NMR was
2.8 nmol mg31. Although the theoretical activity based on the molec-
ular weight of the protein is 10 nmol mg31, such discrepancies be-
tween experimental and theoretical activities have been described pre-
viously and attributed to the bu¡er conditions employed for
neurotensin binding assays [18,20]. The purity of the sample was de-
termined by electrophoresis on a 5^12% gradient SDS^polyacrylamide
gel followed by Coomassie staining. The gels show a single band
consistent with the molecular weight of the expressed construct
(data not shown). The NMR sample consisted of 10 nmol of neuro-
tensin receptor in a 6 mm Chemagnetics rotor sealed to prevent de-
hydration during the course of the experiment. Neurotensin(8^13) was
added sequentially until a stoichiometric quantity had been added,
ensuring that after each addition only a single population of neuro-
tensin(8^13) was present. Neurotensin(8^13) was added as a concen-
trated solution in bu¡er, such that no more that 15 Wl of neuroten-
sin(8^13) was added to each sample.
2.3. NMR methodology
All carbon-13 spectra were acquired at 125.7985 MHz on Chem-
agnetics CMX-500, with triple resonance 6 mm CP-MAS probe. All
carbon-13 spectra were acquired using standard proton-decoupled
carbon-13 acquisition, with a spinning frequency of 500 Hz. Car-
bon-13 pulse lengths were typically 5 Ws and 70 kHz proton decou-
pling was applied during acquisition. All spectra were acquired at 5‡C
unless otherwise stated.
3. Results and discussion
3.1. Assignment
Assignment of neurotensin(8^13) was performed in low-salt
bu¡er used for the ¢nal preparation of the neurotensin recep-
tor prior to binding studies and NMR experiments. The 1D
carbon-13 MAS spectra of neurotensin(8^13) is shown in
Fig. 1. The data obtained under these conditions show good
Table 1
Residue Carbon-13 chemical shift (ppm)
CO CK CL CQ CN Other
Arg1 169.43 (+1.51) 52.08 28.27 24.22 40.39 156.40 (CO)
Arg2 171.24 50.86 27.52 24.22 40.39 156.40 (CO)
Pro3 172.72 59.77 28.30 23.64 47.86
Tyr4 172.05 54.18 35.70 127.26 (30.13) (C1)
130.44 (30.62) (C2,6)
115.14 (30.15) (C3,5)
154.20 (+0.2) (C4)
Ile5 171.76 57.38 35.59 14.34 (+0.11) 9.69 (+0.07)
23.16
Leu6 178.05 (+0.43) 52.78 40.39 24.22 20.80 (+0.27)
22.02
Assignment of neurotensin(8^13) in bu¡er as described in text and the perturbations of resolvable resonances upon binding to the neurotensin
receptor are given in italics. All chemical shifts referenced externally to admantane whose low ¢eld peak is given as 37.6 ppm. For the determi-
nation of perturbations in chemical shift, referencing was con¢rmed from resonances arising from the bu¡er components.
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resolution (linewidths typically 10 Hz), with many of the car-
bon^carbon J-couplings well resolved. With the exception of
the two resonances arising from the natural abundance of
glycerol in the sample (N= 62.2 ppm and N= 71.79 ppm), all
other resonances can be assigned to the uniformly labelled
neurotensin(8^13). On the basis of the distinct chemical shifts
and the observed carbon^carbon and carbon^nitrogen J-cou-
plings, many of the side chain resonances can be readily as-
signed from the proton-decoupled carbon-13 MAS spectra
and by comparison with previously published chemical shifts
on model peptide systems [21]. Assignment of other resonan-
ces was performed on the basis of a 2D-MAS-COSY spectrum
(data no shown) of uniformly carbon-13/nitrogen-15-labelled
neurotensin(8^13) where the backbone CK/CO resonances
were well resolved and could be assigned on the basis of con-
nectivities with side chain resonances. These assignments are
given in Table 1.
3.2. Binding studies
The proton-decoupled spectra of neurotensin receptor in
detergent micelles is shown in Fig. 2A. The spectrum is dom-
inated by two intense resonances at 62 and 71 ppm arising
from the natural abundance carbon-13 within the glycerol
within the sample. Additional intensity is also apparent in
the region between 10 and 80 ppm which has been shown
to arise from natural abundance carbon-13 present in the
CHAPS, dodecyl maltoside and cholesterol hemisuccinate
present in the bu¡er system. Resonances down¢eld from these
have been assigned to natural abundance carbons in the cho-
lesterol hemisuccinate rings and from the carbonyl groups
present in several of the detergent components. From the
spectra presented, no resonances were observed from that
natural abundance carbon-13 present from the detergent-solu-
bilised receptor. We attribute this to the low concentration of
protein present in the sample (10 nmol) with carbon-13
present at only natural abundance levels.
The spectra of detergent-solubilised neurotensin receptor
upon the addition of a stoichiometric amount of uniformly
labelled neurotensin(8^13) is shown in Fig. 2B. The spectrum
is again dominated by intense resonances arising from natural
abundance material within the sample. However, upon the
addition of 10 nmol of neurotensin(8^13), several resonances
clearly appear in the down¢eld region of the spectra (110^185
ppm) (Fig. 3). We attribute these resonances to well-resolved
sites within the side chains of aromatic and basic residues
present in the neurotensin(8^13) on the basis of the similarity
of the chemical shifts with those that have been described for
the neurotensin(8^13) under identical bu¡er condition. In ad-
dition to these well-resolved resonances present in the down-
¢eld region, careful analysis of the aliphatic region allows the
assignment of several of resonances arising from aliphatic
resonances in the leucine and isoleucine side chains. Analyses
of the carbonyl region also shows increased intensity in addi-
tion to that arising from the carbonyl groups from the deter-
gents present, and in several cases carbonyl shifts that were
Fig. 1. Proton-decoupled carbon-13 MAS spectra of 4 mg uniformly
carbon-13/nitrogen-15-labelled neurotensin(8^13) in low-salt bu¡er.
Data acquired at 5‡C and averaged over 1024 acquisitions. Data
zero ¢lled to 32768 points and processed with 3 Hz line broadening
prior to Fourier transform.
Fig. 2. Proton-decoupled carbon-13 MAS spectra of 10 nmol of
neurotensin receptor in low-salt bu¡er (A) and upon the addition of
10 nmol of uniformly carbon-13/nitrogen-15-labelled neurotensin-
(8^13) (U10) (B). Data acquired at 5‡C and averaged over 8192 ac-
quisitions and processed with 3 Hz line broadening prior to Fourier
transform.
Fig. 3. Expansion of carbon-13 MAS spectrum from 110 to 185
ppm of neurotensin(8^13) (A) and neurotensin(8^13) bound to the
detergent-solubilised receptor (B). The spectral region shown con-
tains resonances arising from carbonyl groups and some sites within
the arginine and tyrosine side chains. The assigned sites represent
those for which perturbations where observed upon binding of the
ligand to receptor.
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clearly assignable are no longer present. The perturbations of
these chemical shifts from the values obtained in detergent
bu¡er alone are given in Table 1 (in italics) and for the region
between 110 and 185 ppm indicated in Fig. 3. Although many
of the side chain resonances are well resolved, many of the
backbone CK aliphatic side chains are masked by the presence
of the strong natural abundance from the detergent.
Although many of the perturbations in chemical shift are
relatively small, the good resolution obtained in the system
(line widths typically less than 10 Hz), in addition to the
presence of natural abundance peaks that show no perturba-
tion between the two samples, suggest that the perturbations
observed arise solely from the interaction with the neurotensin
receptor present in the detergent micelles. We preclude the
possibility of non-speci¢c binding on the basis of tritiated
binding assays that show that non-speci¢c binding within
the system is less than 5% of the bound ligands under these
conditions [18,20]. Additionally, the presence of a single dis-
tinct resonance for sites where perturbations have been ob-
served indicates strongly that the neurotensin(8^13) present in
the sample exists in a single, predominantly bound form.
Many of the resolved resonances for labelled neurotensin
(8^13) show either no or only small perturbations in chemical
shift upon binding. However, signi¢cant changes were ob-
served for two of the previously well-resolved carbonyl shifts,
and the tyrosine side chain (Fig. 3). In addition, more subtle
changes were observed for the resonances arising from the
aliphatic side chains present in the neurotensin(8^13). Car-
bon-13 chemical shifts are sensitive to a variety of environ-
mental changes including molecular conformation, local
charged environment and perturbation of the local ¢eld due
to the presence of ring current e¡ects arising from the pres-
ence of aromatic groups in the vicinity (6 4 Aî ) of the labelled
site [22^24]. The perturbations in chemical shifts observed can
be interpreted in terms of molecular rearrangements and
changes in local electrostatic environment upon the binding
of neurotensin to the receptor compared with the receptor in
free solution.
The best characterised carbon-13 chemical shifts are those
arising from protein backbone resonances [25,26]. Although
many of these resonances are poorly resolved, both the car-
bonyl groups from Arg1 and the carboxy terminus were
clearly resolved in the carbon-13 MAS spectra of neurotensin
in detergent bu¡er. Upon binding, the resonance from the
carbonyl group of Arg1 moves down¢eld by 1.51 ppm, such
down¢eld changes in carbonyl chemical shifts in more ex-
tended secondary structural motifs are indicative of the local
region adopting a more helical conformation (iW40‡) [25,26].
However, the absence of assignments for others of the carbon-
yl and CK resonance due to poor site resolution precludes a
more detailed analysis of the backbone conformation. The
relatively high chemical shift of the carboxy terminus in
both the unligated and receptor-bound forms of the neuro-
tensin(8^13) might suggest that the peptide exists in its depro-
tonated state both in solution and when bound. The further
down¢eld shift upon binding suggests that this group might
be interacting with other charged sites within the ligand-bind-
ing site. Such an analysis is consistent with structure^activity
relationship studies which show a two-fold reduction in a⁄n-
ity for the receptor for both neurotensin and neurotensin-
(8^13) upon the conversion of the carboxylic group to an
amide [14]. This observation would also be in agreement
with the site-directed mutagenesis and modelling studies per-
formed by Barroso et al. [11], which suggest the existence a
strong ionic interaction between the carboxy terminus and an
arginine in the agonist-binding site.
Perturbations in the side chain chemical shifts were ob-
served for both of the aliphatic amino acids and tyrosine.
The small perturbations in chemical shift in the aliphatic
side chains suggest that large changes in electrostatic environ-
ment due to changes in conformation or local environment
are observed upon the binding of the ligand to the receptors
do not occur. This observation is consistent with the view that
these residues weakly interact with the agonist-binding site
through hydrophobic interactions [9,11]
Larger perturbations in resonances assigned to the tyrosine
side chain were observed upon the binding of neurotensin- (8^
13) to the receptor. Previous studies have shown that the C1
carbon in the aromatic ring is sensitive to the orientation of
the ring with respect to the backbone [27], and thus perturba-
tions of this resonance might be indicative of a change in
conformation of the side chain upon binding. However, the
information presented here cannot preclude the observed per-
turbation arising from changes in local environment. The per-
turbations observed in the C2,6, C3,5 and C4 resonances
strongly suggest that the tyrosine is interacting with sites with-
in the receptor-binding pocket. Structure^activity studies of
neurotensin and neurotensin(8^13) suggest that the tyrosine
contains vital pharmacophores necessary for binding to the
receptor [14,15] and suggest that the tyrosine side chain may
be involved in both Z^Z stacking and hydrogen bonding with
either receptor or ligand upon receptor binding. These obser-
vations have gained further support from both mutagenesis
and modelling studies [9,11]. The data presented here does not
allow us to deconvolute the possible contributions of such
interactions, but further supports the importance of this
group in the binding and activation of the neurotensin recep-
tor by neurotensin(8^13) and neurotensin.
Resonances arising from the arginine-Ch are also clearly
resolved in the carbon-13 MAS spectra of neurotensin(8^13)
whilst bound to the neurotensin receptor in detergent micelles.
The absence of signi¢cant perturbations in chemical shift sug-
gests the Chs have undergone few detectable changes in elec-
trostatic environment or conformation upon binding to the
receptor. Structure^activity studies suggest that the role of
Arg8 in the binding of neurotensin may be minimal with rel-
atively small changes in a⁄nity upon its modi¢cation [14,15].
These views are supported by several modelling studies which
suggest that the guanidinium group of Arg8 is only interacting
weakly with the receptor [9,11], indicating that few perturba-
tions in chemical shift are expected. In contrast, site-directed
structure^activity and mutagenesis studies have show that the
guanidinium group of Arg9 plays an important role in the
binding of neurotensin (and neurotensin(8^13)) to the recep-
tor [9,11]. The absence of any detectable change in either of
the two arginine-Ch resonances would suggest that the pro-
posed interactions between the guanidinium group and aro-
matic systems within the binding site are weak, with neither of
the guanidinium groups approaching aromatic systems closer
than (4^5 Aî ). This might be due to the central location of the
carbon atom in the centre of the guanidinium group which
would preclude close contacts, in agreement with the ligand
geometries proposed by Pang et al. [9] on the basis of mod-
elling and site-directed mutagenesis studies.
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4. Conclusions
The above results indicate that su⁄cient resolution in the
carbon-13 NMR spectra is attainable through the application
of slow magic angle sample spinning and high-power proton
decoupling to permit a detailed analysis of the chemical shifts
of neurotensin(8^13) whilst bound to detergent-solubilised re-
ceptor. Although many of the backbone and aliphatic reso-
nances arising from carbon-13 sites within the neurotensin(8^
13) were obscured by strong resonances arising from natural
abundance carbon-13 within the bu¡er system, many of the
sites from aromatic and basic side chains were clearly resolv-
able. The perturbations in chemical shift observed upon the
binding of the neurotensin(8^13) to the detergent-solubilised
receptor indicate key residues that are important in the bind-
ing of the neurotensin to the receptor. The magnitude of the
perturbations observed for both the tyrosine side chain and
the carboxy terminus indicate clearly that these sites interact
strongly with the receptor upon binding. These direct obser-
vations are in good agreement with observations from site-
directed mutagenesis, structure^function and modelling stud-
ies of neurotensin(8^13) interacting with the neurotensin re-
ceptor.
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